Apixaban
Ampulla of Vater Cancer
Asan Medical CenterSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Ampulla of Vater Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rivaroxaban Asan Medical Center | Phase 2 | CCC |
Fragmin Asan Medical Center | Phase 2 | CCC |
CIS-DIAMMINEDICHLOROPLATINUM II University of Nebraska | Phase 1 | CC |
FLUOROURACILUM University of Chicago | Phase 1 | CC |
Irinotecan University of Chicago | Phase 1 | CC |
ADH-1 TRIFLUROACETATE University of Nebraska | Phase 1 | CC |
Same molecule, other indications
Apixaban is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →